Welcome to LookChem.com Sign In|Join Free


  • or


Post Buying Request

110506-85-9 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

110506-85-9 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 110506-85-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,0,5,0 and 6 respectively; the second part has 2 digits, 8 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 110506-85:
79 % 10 = 9
So 110506-85-9 is a valid CAS Registry Number.



According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 15, 2017

Revision Date: Aug 15, 2017


1.1 GHS Product identifier

Product name 5-hydroxy-2-phenyl-7-phenylmethoxychromen-4-one

1.2 Other means of identification

Product number -
Other names 4H-1-Benzopyran-4-one,5-hydroxy-2-phenyl-7-(phenylmethoxy)

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:110506-85-9 SDS

110506-85-9Relevant articles and documents

Directional modification of chrysin for exerting apoptosis and enhancing significantly anti-cancer effects of 10-hydroxy camptothecin

Tang, Qin,Ji, Fangling,Guo, Jianli,Wang, Jingyun,Li, Yachen,Bao, Yongming

, p. 693 - 703 (2016)

Chrysin, one of natural flavonoid compounds, has recently been found to possess anti-inflammatory, antiallergic and anticancer properties. To increase its anticancer effects, 5 chrysin derivates were synthesized on the base of DNA intercalator structure.

Novel compound and composition for prevention, improvement or treatment of fibrosis or non-alcoholic steatohepatitis comprising the same


Paragraph 0064-0066, (2018/08/12)

The present invention relates to a novel compound and a composition for prevention, improvement, or treatment of fibrosis or nonalcoholic steatohepatitis comprising the same as an active ingredient. More specifically, the present invention relates to a novel compound of chemical formula 1 which has an excellent effect for prevention, improvement, or treatment of fibrosis and a composition for prevention, improvement, or treatment of fibrosis or nonalcoholic steatohepatitis comprising the same as an active ingredient. A novel compound of the present invention effectively controls expression of snail and vimentin which are a controlling element of Epithelial Mesenchymal Transition (EMT) and controls activation of EMT, and thus effectively prevents, improves, or treats fibrosis accordingly. Additionally, a novel compound of the present invention has a very excellent pharmacokinetic characteristic, and thus can perform fast drug delivery to the body through oral administration, stably displays an effect in the body, and is secure to use without a big side effect. Moreover, since a novel compound of the present invention can effectively block fibrosis of a hepatic cell, nonalcoholic steatohepatitis can effectively improved or treated.(AA) Chemical formula 1COPYRIGHT KIPO 2018

Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors

Liu, Tao,Nair, Somarajan J.,Lescarbeau, Andre,Belani, Jitendra,Peluso, Stephane,Conley, James,Tillotson, Bonnie,OHearn, Patrick,Smith, Sherri,Slocum, Kelly,West, Kip,Helble, Joseph,Douglas, Mark,Bahadoor, Adilah,Ali, Janid,McGovern, Karen,Fritz, Christian,Palombella, Vito J.,Wylie, Andrew,Castro, Alfredo C.,Tremblay, Martin R.

, p. 8859 - 8878,20 (2020/09/16)

Misregulation of protein translation plays a critical role in human cancer pathogenesis at many levels. Silvestrol, a cyclopenta[b]benzofuran natural product, blocks translation at the initiation step by interfering with assembly of the eIF4F translation complex. Silvestrol has a complex chemical structure whose functional group requirements have not been systematically investigated. Moreover, silvestrol has limited development potential due to poor druglike properties. Herein, we sought to develop a practical synthesis of key intermediates of silvestrol and explore structure-activity relationships around the C6 position. The ability of silvestrol and analogues to selectively inhibit the translation of proteins with high requirement on the translation-initiation machinery (i.e., complex 5′-untranslated region UTR) relative to simple 5′UTR was determined by a cellular reporter assay. Simplified analogues of silvestrol such as compounds 74 and 76 were shown to have similar cytotoxic potency and better ADME characteristics relative to those of silvestrol.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)


What can I do for you?
Get Best Price

Get Best Price for 110506-85-9